Epoxytigliane Modulation of Dermal Fibroblast-Myofibroblast Wound Healing Responses Mediate Enhanced Anti-Scarring Properties via Classical Protein Kinase C Activation

Epoxytiglianes are a novel class of diterpene esters. Prototype epoxytigliane, EBC-46 (tigilanol tiglate), possesses potent anti-cancer properties and is being developed as a human/veterinary tumor treatment. EBC-46 mediates such tumoricidal effects in part via classical protein kinase C (PKC) activation; and consistently promotes desirable wound healing outcomes at treated tumor sites, including minimal scarring. As the mechanisms underlying these anti-scarring responses are poorly understood, we investigated the effects of 1.51 nM-151 µM EBC-46 and analogue (EBC-211) on scarring responses in dermal fibroblasts and myofibroblasts. EBC-46 and EBC-211 significantly inhibited G1/S and S/G2 cell cycle transitions and fibroblast proliferation; with limited effects on migration. Both epoxytiglianes induced concentration-dependent inhibitory effects on transforming growth factor-β1 (TGF-β1)-driven fibroblast-myofibroblast differentiation at 151 nM EBC-46 and 15.1 µM EBC-211, with significantly reduced α-smooth muscle actin (αSMA) gene (ACTA2) expression and stress fiber formation. Epoxytiglianes were shown to modulate myofibroblast gene expression profiles associated with the cytoskeleton, extracellular matrix and proteolytic remodeling, in favor of scar resolution. PKC inhibitors (bisindolylmaleimide-1, GÖ6976) both attenuated epoxytigliane inhibition of myofibroblast formation. By identifying how epoxytiglianes induce minimal scarring outcomes in treated skin, we highlight the potential of epoxytiglianes as novel therapeutics for clinical situations associated with excessive dermal scarring.

Authors

Publication Details

Journal
Preprints.org
Published
2026-11-16
DOI
https://doi.org/10.20944/preprints202611.1507.v1
Primary Topic
Dermatologic Treatments and Research
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Epoxytigliane Modulation of Dermal Fibroblast-Myofibroblast Wound Healing Responses Mediate Enhanced Anti-Scarring Properties via Classical Protein Kinase C Activation

Ryan Moseley, Emma Louise Woods, Jenny P. Johns, Rachel J. Errington et al.
Preprints.org
Dermatologic Treatments and Research
preprint

Epoxytigliane Modulation of Dermal Fibroblast-Myofibroblast Wound Healing Responses Mediate Enhanced Anti-Scarring Properties via Classical Protein Kinase C Activation

Ryan Moseley, Emma Louise Woods, Jenny P. Johns, Rachel J. Errington, Rachel Anne Howard-Jones, Jordanna Dally, Rachael L. Moses, Glen M. Boyle, Jason K. Cullen, Paul Reddell, Robert Steadman, Victoria Gordon
preprint en

Abstract

Epoxytiglianes are a novel class of diterpene esters. Prototype epoxytigliane, EBC-46 (tigilanol tiglate), possesses potent anti-cancer properties and is being developed as a human/veterinary tumor treatment. EBC-46 mediates such tumoricidal effects in part via classical protein kinase C (PKC) activation; and consistently promotes desirable wound healing outcomes at treated tumor sites, including minimal scarring. As the mechanisms underlying these anti-scarring responses are poorly understood, we investigated the effects of 1.51 nM-151 µM EBC-46 and analogue (EBC-211) on scarring responses in dermal fibroblasts and myofibroblasts. EBC-46 and EBC-211 significantly inhibited G1/S and S/G2 cell cycle transitions and fibroblast proliferation; with limited effects on migration. Both epoxytiglianes induced concentration-dependent inhibitory effects on transforming growth factor-β1 (TGF-β1)-driven fibroblast-myofibroblast differentiation at 151 nM EBC-46 and 15.1 µM EBC-211, with significantly reduced α-smooth muscle actin (αSMA) gene (ACTA2) expression and stress fiber formation. Epoxytiglianes were shown to modulate myofibroblast gene expression profiles associated with the cytoskeleton, extracellular matrix and proteolytic remodeling, in favor of scar resolution. PKC inhibitors (bisindolylmaleimide-1, GÖ6976) both attenuated epoxytigliane inhibition of myofibroblast formation. By identifying how epoxytiglianes induce minimal scarring outcomes in treated skin, we highlight the potential of epoxytiglianes as novel therapeutics for clinical situations associated with excessive dermal scarring.

Preprints.org
Good health and well-being
Dermatologic Treatments and Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon